T he physical manifestation of a trait is a constant interplay between one's genetic makeup and environmental factors. This notion has been substantiated by nutrigenomic studies demonstrating the benefits of nutritional supplements along the continuum between health and disease. 1 More importantly, these studies have revealed the plasticity by which the genetic substrate can interact with various environmental components to either exacerbate or mitigate the manifestation of a disease process in those genetically predisposed.
Focusing on cardiovascular disease, a vast literature has demonstrated that this disease process is associated with impaired energy production, increased oxidative stress, and cell calcium overload. To these ends, both clinical and animal studies have demonstrated nutrient deficiencies, integral to these processes, to be associated with cardiovascular disease and that these deficiencies represent independent predictors of increased morbidity and mortality. 2, 3 One cellular component that has received considerable attention regarding function and nutrient supplementation is the mitochondria.
Mitochondria are responsible for cellular bioenergetics via oxidative phosphorylation. However, the perpetual transfer of electrons from one molecule to another within the mitochondria renders this organelle a major site for the genesis of reactive oxygen species (ROS). 4 Although the mitochondria have antioxidant defenses, 4 the disequilibrium between ROS production and ROS neutralization paves the way for disease manifestation.
ROS damage to mitochondrial proteins, lipids, and DNA poses a serious detriment to the mitochondria. In particular, knockout experiments of key mitochondrial oxidative defenses are associated with the onset of cardiovascular disease, whereas their overexpression is capable of forestalling the onset of disease. 5 Conversely, supplementation of specific antioxidants has been shown to mitigate the disease state in animal models. 5 However, it is difficult to determine with alacrity the contribution that mitochondrial-derived ROS may have on cardiovascular disease. 5 To this end, the work by Graham et al 6 published in this issue of Hypertension demonstrated the extent that mitochondrial-derived ROS contributes to cardiovascular disease.
Coenzyme Q 10 (CoQ 10 ) is an endogenous compound found in the inner mitochondrial membrane that is essential to electron transport and ATP production via the respiratory chain ( Figure, (a) ). In addition to its role in bioenergetics, supplementation with CoQ 10 has been shown to inhibit thrombus formation and to reduce ROS 7 ( Figure, (b) ). Both clinical and rodent studies have demonstrated moderate beneficial actions of CoQ 10 in reducing blood pressure, decreasing blood glucose, forestalling myocardial damage secondary to chemotherapeutic administration, limiting tumor growth, enhancing endothelial function, and improving cognitive function in both Alzheimer's and Parkinson patients. 7 However, one of the major limiting factors in the use of CoQ 10 as a supplement is its bioavailability and delivery to the source of ROS generation.
Using a mitochondria-targeted lipophilic triphenylphosphonium cation covalently bound to ubiquinol, MitoQ 10 , Graham et al 6 demonstrated that oral administration of this formulation of CoQ 10 reduced blood pressure, increased the bioavailability of NO, and reduced cardiac hypertrophy in a rodent model genetically predisposed to high blood pressure and stroke. Moreover, mass spectrometry demonstrated significant ubiquinol content in liver, heart, carotid, and kidney tissues. 6 Conversely, the lipophilic cation used to target ubiquinol to the mitochondria had no beneficial actions. 6 Therefore, the significance of this work is 2-fold. First, it demonstrated the benefits of ubiquinol. Second, it demonstrated the enhanced delivery of CoQ 10 to a specific target. In addition, this study reinforced the importance of CoQ 10 supplementation. However, at the same time, these findings have raised some important questions regarding CoQ 10 .
Although coenzyme Q 10 is an essential component of the respiratory chain and protects the mitochondrial and cell membranes from lipid oxidation, it also functions as a cofactor for uncoupling proteins 8 (Figure, (c) ). Uncoupling proteins are, in essence, the molecular switch that change the end product of the respiratory chain from an ATP producer to that of heat generator. 8 Several studies have demonstrated that uncoupling proteins reduce ROS and that CoQ 10 is an essential cofactor for these uncoupling proteins. 8 Therefore, CoQ 10 , along with uncoupling proteins, may play a role in ROS-dependent signaling pathways, and the ratio of oxidized:reduced CoQ 10 may also play an important signaling role. This notion is of particular interest, because CoQ 10 has been shown to be a potent gene regulator. Specifically, CoQ 10 caused an increased expression of hundreds of genes in human cell lines. 9 Although the molecular mechanisms whereby CoQ 10 is imparting these pleiotropic effects has yet to be discerned, 9 CoQ 10 may have a more far-reaching action than simply as an antioxidant.
Another important question raised by the study by Graham et al 6 relates to who can benefit from this formulation of CoQ 10 and what other circumstances would warrant its administration. By demonstrating the salutary actions of MitoQ 10 in stroke-prone spontaneously hypertensive rats, Graham et al 6 demonstrated the beneficial role of CoQ 10 supplementation in a model genetically predisposed to cardiovascular disease and, thus, mitigated the cardiovascular sequelae associated with this particular rodent strain. 6 Therefore, we are only left to speculate as to the immense impact that this compound could have in medicine. One specific and sometimes controversial area that first comes to mind is the adverse effects of certain cholesterol-lowering medication and its action on endogenous CoQ 10 production. 10 Endogenous production of CoQ 10 occurs via a shared pathway, which uses 3-hydroxy-3-methyl-glutaryl-CoA reductase, the rate-limiting reaction of the mevalonate pathway (see the Figure) . This metabolic pathway produces cholesterol and other isoprenoids, the later of which are required by CoQ 10 to anchor it in the inner membrane of the mitochondria. 10 Therefore, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductases decrease the endogenous pool of CoQ 10 . Thus, formulations like MitoQ 10 could be beneficial to those patients taking cholesterol-lowering drugs. On the basis of this notion, the work by Graham et al 6 has demonstrated that CoQ 10 supplementation represents a novel adjunct to conventional therapeutic modalities and may become an essential component for disease prevention to reduce the incidences of cardiovascular disease.
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